American Society of Hematology

Figure 1.

$Identification of PTP-MEG2 by chromatographic fractionation and immunoblotting. Cytosolic (A) and membrane (B) extracts of day 6 PV ECFCs were separated on an FPLC anionic-exchange Mono-Q column. Samples corresponding to the activity peak in panel B (fractions 41-43) were combined and further separated on an FPLC Superose-12 gel filtration column (C). PTP activity was analyzed as described in “Materials and methods.” Protein levels of PTP-MEG2 and SHP-1 in the indicated fractions were determined by Western blotting analyses with anti-PTP-MEG2 and anti-SHP-1 antibodies, respectively. Representative data from at least 4 independent experiments are shown. Similar results were seen with normal ECFCs except for a lower total PTP activity in the membrane extracts.$

Identification of PTP-MEG2 by chromatographic fractionation and immunoblotting. Cytosolic (A) and membrane (B) extracts of day 6 PV ECFCs were separated on an FPLC anionic-exchange Mono-Q column. Samples corresponding to the activity peak in panel B (fractions 41-43) were combined and further separated on an FPLC Superose-12 gel filtration column (C). PTP activity was analyzed as described in “Materials and methods.” Protein levels of PTP-MEG2 and SHP-1 in the indicated fractions were determined by Western blotting analyses with anti-PTP-MEG2 and anti-SHP-1 antibodies, respectively. Representative data from at least 4 independent experiments are shown. Similar results were seen with normal ECFCs except for a lower total PTP activity in the membrane extracts.

This Feature Is Available To Subscribers Only